Clinical Trial

Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have previously undergone deep brain stimulation or deep brain nucleus lesioning surgery.
Trial Details
NCT Number NCT07550374
Lead Sponsor iRegene Therapeutics Co., Ltd.
Conditions Parkinson's Disease (PD)
Enrollment 10 participants
Start Date 2026-05
Primary Completion 2028-04 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-04-24